X - PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
X - PHARMA
Largest movements
- Cash +€12,847
up €12,847 (+16.0%), from €80,204 to €93,051
mainly Net result for the year (+€9,962) and Receivables within one year (+€5,861)
- Receivables within one year -€5,861
down €5,861 (-34.1%), from €17,203 to €11,342
of which Trade receivables: -€5,408
- Reserves +€9,500
up €9,500 (+13.8%), from €68,830 to €78,330
of which Distributable reserves: +€9,000
- Tax, wage and social debts -€2,632
down €2,632 (-76.4%), from €3,444 to €812
- Financial income -€11,136
no longer reported in 2025 (was €11,136)
- Taxes -€3,665
down €3,665 (-44.8%), from €8,185 to €4,521
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €143,164 | €150,150 | +€6,986 | +4.9% |
| Fixed assets | 21/28 | €45,757 | €45,757 | = | 0.0% |
| Tangible fixed assets | 22/27 | €0 | €0 | = | |
| Furniture and vehicles | 24 | €0 | €0 | = | |
| Financial fixed assets | 28 | €45,757 | €45,757 | = | 0.0% |
| Current assets | 29/58 | €97,407 | €104,393 | +€6,986 | +7.2% |
| Amounts receivable within one year | 40/41 | €17,203 | €11,342 | -€5,861 | -34.1% |
| Trade receivables | 40 | €5,408 | - | -€5,408 | |
| Other amounts receivable | 41 | €11,795 | €11,342 | -€453 | -3.8% |
| Cash at bank and in hand | 54/58 | €80,204 | €93,051 | +€12,847 | +16.0% |
| Total equity and liabilities | 10/49 | €143,164 | €150,150 | +€6,986 | +4.9% |
| Equity | 10/15 | €138,425 | €148,387 | +€9,962 | +7.2% |
| Contributions | 10/11 | €62,000 | €62,000 | = | 0.0% |
| Capital | 10 | €62,000 | €62,000 | = | 0.0% |
| Issued capital | 100 | €62,000 | €62,000 | = | 0.0% |
| Reserves | 13 | €68,830 | €78,330 | +€9,500 | +13.8% |
| Non-distributable reserves | 130/1 | €5,430 | €5,930 | +€500 | +9.2% |
| Legal reserve | 130 | €5,430 | €5,930 | +€500 | +9.2% |
| Distributable reserves | 133 | €63,400 | €72,400 | +€9,000 | +14.2% |
| Profit (loss) carried forward | 14 | €7,595 | €8,057 | +€462 | +6.1% |
| Amounts payable | 17/49 | €4,739 | €1,763 | -€2,977 | -62.8% |
| Amounts payable within one year | 42/48 | €4,739 | €1,763 | -€2,977 | -62.8% |
| Trade debts | 44 | €1,295 | €951 | -€344 | -26.6% |
| Suppliers | 440/4 | €1,295 | €951 | -€344 | -26.6% |
| Taxes, remuneration and social security | 45 | €3,444 | €812 | -€2,632 | -76.4% |
| Taxes | 450/3 | €3,444 | €812 | -€2,632 | -76.4% |
| Other operating charges | 640/8 | €642 | €659 | +€17 | +2.7% |
| Gross operating margin | 9900 | €15,485 | €15,417 | -€68 | -0.4% |
| Operating profit (loss) | 9901 | €14,844 | €14,758 | -€85 | -0.6% |
| Financial income | 75/76B | €11,136 | - | -€11,136 | |
| Recurring financial income | 75 | €11,136 | - | -€11,136 | |
| Financial charges | 65/66B | €238 | €275 | +€37 | +15.5% |
| Recurring financial charges | 65 | €238 | €275 | +€37 | +15.5% |
| Profit (loss) for the period before taxes | 9903 | €25,742 | €14,483 | -€11,259 | -43.7% |
| Income taxes | 67/77 | €8,185 | €4,521 | -€3,665 | -44.8% |
| Profit (loss) for the period | 9904 | €17,556 | €9,962 | -€7,594 | -43.3% |
| Profit (loss) for the period to be appropriated | 9905 | €17,556 | €9,962 | -€7,594 | -43.3% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 1 October 2026 via checked.be.